Kathy Yi
Chief Operating Officer at Affini-T Therapeutics, Inc.
Profile
Kathy Yi is on the board of Sangamo Therapeutics UK Ltd. and Theseus Pharmaceuticals, Inc. In the past Ms. Yi held the position of CFO, Secretary, Principal Accounting Officer & EVP at Sangamo Therapeutics, Inc., Chief Financial Officer at Cerevel Therapeutics Holdings, Inc., Director-Finance & Corporate Development at Life Technologies Corp. and Head-Finance, Inhalation Technical R&D at Novartis Pharmaceuticals Corp. She received an undergraduate degree from the University of California, Berkeley and an MBA from Columbia Business School.
Kathy Yi active positions
Companies | Position | Start |
---|---|---|
Sangamo Therapeutics UK Ltd.
Sangamo Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Sangamo Therapeutics UK Ltd. researches and develops transcription factors in the regulation of genes. The company was founded on April 21, 1999 and is headquartered in Cheltenham, the United Kingdom. | Director/Board Member | 2017-02-27 |
Affini-T Therapeutics, Inc.
Affini-T Therapeutics, Inc. BiotechnologyHealth Technology Affini-T Therapeutics, Inc. is a biotechnology company based in Watertown, MA. Affini-t is focused on developing potentially curative therapies for solid tumor cancers by unlocking the power of T cells and targeting core oncogenic drivers. The company's differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company is targeting Kras and other oncogenic and viral driver mutations to open a new and differentiated target space, thereby minimizing the risk of cancer. The company was founded by Jak Knowles and Arjun Goyal, with Jak Knowles serving as the CEO since incorporation. | Chief Operating Officer | - |
Former positions of Kathy Yi
Companies | Position | End |
---|---|---|
THESEUS PHARMACEUTICALS, INC. | Director/Board Member | 2024-02-13 |
CEREVEL THERAPEUTICS HOLDINGS, INC. | Director of Finance/CFO | 2021-09-19 |
SANGAMO THERAPEUTICS, INC. | Director of Finance/CFO | 2019-06-06 |
Life Technologies Corp.
Life Technologies Corp. Miscellaneous Commercial ServicesCommercial Services Life Technologies Corp. provides products in the areas of scientific research, genetic analysis and applied sciences. Its brands include Invitrogen, Applied Biosystems, Gibco, Molecular Probes, Noves, Ambion and Ion Torrent. The firm’s portfolio includes the most cited products and technologies in qPCR, capillary electrophoresis sequencing, nextgeneration sequencing, molecular diagnostics, forensics, cell culture and analysis, and agriculture research. The company was founded on November 21, 2008 and is headquartered in Carlsbad, CA. | Director of Finance/CFO | 2013-12-31 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | - |
Training of Kathy Yi
University of California, Berkeley | Undergraduate Degree |
Columbia Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
SANGAMO THERAPEUTICS, INC. | Health Technology |
CEREVEL THERAPEUTICS HOLDINGS, INC. | Health Technology |
Private companies | 5 |
---|---|
Sangamo Therapeutics UK Ltd.
Sangamo Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Sangamo Therapeutics UK Ltd. researches and develops transcription factors in the regulation of genes. The company was founded on April 21, 1999 and is headquartered in Cheltenham, the United Kingdom. | Commercial Services |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Life Technologies Corp.
Life Technologies Corp. Miscellaneous Commercial ServicesCommercial Services Life Technologies Corp. provides products in the areas of scientific research, genetic analysis and applied sciences. Its brands include Invitrogen, Applied Biosystems, Gibco, Molecular Probes, Noves, Ambion and Ion Torrent. The firm’s portfolio includes the most cited products and technologies in qPCR, capillary electrophoresis sequencing, nextgeneration sequencing, molecular diagnostics, forensics, cell culture and analysis, and agriculture research. The company was founded on November 21, 2008 and is headquartered in Carlsbad, CA. | Commercial Services |
Theseus Pharmaceuticals, Inc.
Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |
Affini-T Therapeutics, Inc.
Affini-T Therapeutics, Inc. BiotechnologyHealth Technology Affini-T Therapeutics, Inc. is a biotechnology company based in Watertown, MA. Affini-t is focused on developing potentially curative therapies for solid tumor cancers by unlocking the power of T cells and targeting core oncogenic drivers. The company's differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company is targeting Kras and other oncogenic and viral driver mutations to open a new and differentiated target space, thereby minimizing the risk of cancer. The company was founded by Jak Knowles and Arjun Goyal, with Jak Knowles serving as the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Kathy Yi